» Authors » Annika Asplund

Annika Asplund

Explore the profile of Annika Asplund including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 15
Citations 258
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Ulvestad M, Nordell P, Asplund A, Rehnstrom M, Jacobsson S, Holmgren G, et al.
Biochem Pharmacol . 2013 Jul; 86(5):691-702. PMID: 23856292
Human embryonic and induced pluripotent stem cell-derived hepatocytes (hESC-Hep and hiPSC-Hep) have the potential to provide relevant human in vitro model systems for toxicity testing and drug discovery studies. In...
12.
Asplund A, Friden V, Stillemark-Billton P, Camejo G, Bondjers G
Atherosclerosis . 2011 Jan; 215(1):77-81. PMID: 21247579
Macrophages are prominent in hypoxic areas of atherosclerotic lesions. Their secreted proteoglycans (PG) can modulate the retention of lipoproteins as well as the activity of enzymes, cytokines, and growth factors...
13.
Asplund A, Stillemark-Billton P, Larsson E, Rydberg E, Moses J, Mattsson Hulten L, et al.
Glycobiology . 2009 Sep; 20(1):33-40. PMID: 19748976
Macrophages are prominent in hypoxic areas of atherosclerotic lesions, and their secreted proteoglycans (PG), such as versican, can modulate the retention of lipoproteins and the activity of enzymes, cytokines, and...
14.
Asplund A, Ostergren-Lunden G, Camejo G, Stillemark-Billton P, Bondjers G
J Leukoc Biol . 2009 Apr; 86(2):381-8. PMID: 19401393
Macrophages are recruited and retained in hypoxic sites in atherosclerotic lesions and tumors. Furthermore, macrophages are suggested to be a major source of HSPG synthesis in atherosclerotic lesions. HSPG are,...
15.
Asplund A, Bottiger Y
Lakartidningen . 2007 Jan; 103(49):3954. PMID: 17212276
No abstract available.